FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983708472> ?p ?o ?g. }

• W1983708472 endingPage "267" @default.
• W1983708472 startingPage "266" @default.
• W1983708472 abstract "We read with great interest the AASLD Practice Guideline1 on the diagnosis, management and treatment of hepatitis C (HCV). However, we have some concerns about the definition of HCV carriers with normal alanine aminotransferase (ALT) given by Strader et al.1 In this paper, a person is considered to have normal ALT levels when “there have been two or more determinations identified to be in the normal range over 6 or more months.” In our opinion, this definition could be misleading, as this observation period is too short and thus not adequate to discriminate between “true” HCV carriers with persistently normal ALT levels (PNAL) and patients with only transient biochemical remission. It is known that during the course of HCV infection ALT could fluctuate, with long periods of biochemical remission.2 Thus, it has been suggested that at least two different subsets of HCV carriers exist: patients with wide temporal ALT fluctuations that could be within the normal range for several months or years, and true “biochemically silent” carriers showing persistently normal ALT values.3 It is not known whether these subgroups have different natural history and disease progression.4 In clinical practice, increases in the aminotransferase levels are not uncommon, even at intervals longer than 6 months. Two recent prospective studies5, 6 found that many subjects referred as to HCV carriers with PNAL on the basis of a 6-month observation period did suffer from ALT flares during the follow-up. In our study,5 21% of the patients showed ALT flare-ups during a 34-month follow-up period (range, 24-48 months), and Martinot-Peignoux et al.6 found ALT increase even after 60 months of follow-up, thus proving that even prolonged observation periods might be not adequate to distinguish patients with persistent or transient ALT normality. Thus the observation period should not be shorter than 12–18 months, and ALT determinations should be performed every 2 to 3 months. It is possible that the different degree of liver damage observed in different studies as well as the different prevalence of true “healthy” HCV carriers could be due at least in part to the fact that also patients with transiently normal ALT could have been included in these studies.4 In the light of these data, the Committee for HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver suggested that the definition of HCV carriers with PNAL should be made on the basis of at least 9 normal ALT values 2 months apart over a 18-month period.7 Liver histological activity was found to be significantly more severe among subjects with ALT flares during the follow-up than in those with PNAL.4 Although a comparison between different studies is difficult, the extent of liver damage varied considerably according to the different definitions of normal aminotransferase values, to the varying observation periods, and to the different frequency of the enzyme tests. In particular, the prevalence of severe forms was higher in studies where the period of observation was limited to 6 months, whereas it was lower in the studies with longer observation periods.7 In conclusion, persistently normal ALT level is really a function of the stringency of follow-up and therefore depends on the frequency of ALT determinations. A single normal ALT value may not be representative of the true pattern of ALT levels for a particular patient. Because of the characteristic fluctuating pattern of ALT values in chronic hepatitis C, only more stringent tests (in terms of number and frequency of ALT evaluations) will make it possible to distinguish subjects with persistently normal ALT values from those in temporary biochemical remission. An observation period of 6 months must therefore be considered inadequate, and, more importantly, the definition should not be based on sporadic ALT determination. Claudio Puoti*, Lia Bellis*, Roberto Castellacci*, Fabrizio Montagnese*, Nicoletta Bergami*, Patrizia Petrone De Luca*, * Department of Gastroenterology and Internal Medicine, Genzano Hospital, Rome, Italy." @default.
• W1983708472 created "2016-06-24" @default.
• W1983708472 creator A5003052507 @default.
• W1983708472 creator A5040252725 @default.
• W1983708472 creator A5053483781 @default.
• W1983708472 creator A5056215093 @default.
• W1983708472 creator A5063742617 @default.
• W1983708472 creator A5082140933 @default.
• W1983708472 date "2004-01-01" @default.
• W1983708472 modified "2023-09-25" @default.
• W1983708472 title "HCV carriers with persistently normal aminotransferase levels" @default.
• W1983708472 cites W1980660411 @default.
• W1983708472 cites W2010433970 @default.
• W1983708472 cites W2033992157 @default.
• W1983708472 cites W2037747512 @default.
• W1983708472 cites W2047208492 @default.
• W1983708472 cites W2074620975 @default.
• W1983708472 cites W4246506823 @default.
• W1983708472 doi "https://doi.org/10.1002/hep.20311" @default.
• W1983708472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15239112" @default.
• W1983708472 hasPublicationYear "2004" @default.
• W1983708472 type Work @default.
• W1983708472 sameAs 1983708472 @default.
• W1983708472 citedByCount "3" @default.
• W1983708472 countsByYear W19837084722014 @default.
• W1983708472 countsByYear W19837084722017 @default.
• W1983708472 crossrefType "journal-article" @default.
• W1983708472 hasAuthorship W1983708472A5003052507 @default.
• W1983708472 hasAuthorship W1983708472A5040252725 @default.
• W1983708472 hasAuthorship W1983708472A5053483781 @default.
• W1983708472 hasAuthorship W1983708472A5056215093 @default.
• W1983708472 hasAuthorship W1983708472A5063742617 @default.
• W1983708472 hasAuthorship W1983708472A5082140933 @default.
• W1983708472 hasBestOaLocation W19837084721 @default.
• W1983708472 hasConcept C126322002 @default.
• W1983708472 hasConcept C203014093 @default.
• W1983708472 hasConcept C2776455275 @default.
• W1983708472 hasConcept C2778606649 @default.
• W1983708472 hasConcept C2779134260 @default.
• W1983708472 hasConcept C2992872382 @default.
• W1983708472 hasConcept C71924100 @default.
• W1983708472 hasConcept C90924648 @default.
• W1983708472 hasConceptScore W1983708472C126322002 @default.
• W1983708472 hasConceptScore W1983708472C203014093 @default.
• W1983708472 hasConceptScore W1983708472C2776455275 @default.
• W1983708472 hasConceptScore W1983708472C2778606649 @default.
• W1983708472 hasConceptScore W1983708472C2779134260 @default.
• W1983708472 hasConceptScore W1983708472C2992872382 @default.
• W1983708472 hasConceptScore W1983708472C71924100 @default.
• W1983708472 hasConceptScore W1983708472C90924648 @default.
• W1983708472 hasIssue "1" @default.
• W1983708472 hasLocation W19837084721 @default.
• W1983708472 hasLocation W19837084722 @default.
• W1983708472 hasOpenAccess W1983708472 @default.
• W1983708472 hasPrimaryLocation W19837084721 @default.
• W1983708472 hasRelatedWork W1485973300 @default.
• W1983708472 hasRelatedWork W1735154031 @default.
• W1983708472 hasRelatedWork W1992906557 @default.
• W1983708472 hasRelatedWork W2169202035 @default.
• W1983708472 hasRelatedWork W2361058097 @default.
• W1983708472 hasRelatedWork W2368217940 @default.
• W1983708472 hasRelatedWork W2739774394 @default.
• W1983708472 hasRelatedWork W2745950292 @default.
• W1983708472 hasRelatedWork W307921490 @default.
• W1983708472 hasRelatedWork W3110810440 @default.
• W1983708472 hasVolume "40" @default.
• W1983708472 isParatext "false" @default.
• W1983708472 isRetracted "false" @default.
• W1983708472 magId "1983708472" @default.
• W1983708472 workType "article" @default.